Litigation Details for BAUSCH HEALTH IRELAND LIMITED v. AUROBINDO PHARMA LIMITED (D.N.J. 2023)

BAUSCH HEALTH IRELAND LIMITED v. AUROBINDO PHARMA LIMITED (D.N.J. 2023)

Docket		Date Filed	2023-01-12
Court	District Court, D. New Jersey	Date Terminated	2023-10-30
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Jessica S. Allen
Patents	10,011,637; 11,142,549; 11,319,346; 7,041,786; 9,610,321; 9,616,097; 9,919,024; 9,925,231
Link to Docket	External link to docket

Details for BAUSCH HEALTH IRELAND LIMITED v. AUROBINDO PHARMA LIMITED (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-01-12				External link to document
2023-01-12	1	Complaint	the ’097 patent”), 9,919,024 (“the ’024 patent”), 9,925,231 (“the ’231 patent”), 10,011,637 (“the ’637…’786 patent, the ’321 patent, the ’097 patent, the ’024 patent, the ’231 patent, the ’637 patent, the…’786 patent, the ’321 patent, the ’097 patent, the ’024 patent, the ’231 patent, the ’637 patent, the…786 patent, the ’321 patent, the ’097 patent, the ’024 patent, the ’231 patent, the ’637 patent, the …to the ’321 patent, the ’097 patent, the ’024 patent, the ’231 patent, or the ’637 patent. 34	External link to document
2023-01-12	34	Order of Dismissal	certification to U.S. Patent Nos. 7,041,786, 9,610,321, 9,616,097, 9,919,024, 9,925,231, 10,011,637, 11,142,549…2023 30 October 2023 2:23-cv-00170 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Bausch Health Ireland v. Aurobindo Pharma: Xifaxan Patent Litigation Summary, Case No. 2:23-cv-00170

Last updated: August 8, 2026

Bausch Health Ireland Limited’s action against Aurobindo Pharma Limited is a Hatch-Waxman patent case concerning Aurobindo’s abbreviated new drug application for generic Xifaxan, the rifaximin product marketed by Salix Pharmaceuticals, a Bausch Health company. The case was filed in the U.S. District Court for the District of Delaware in February 2023 and sought to prevent FDA approval or commercial launch of Aurobindo’s proposed generic before expiration of the asserted rifaximin patents. [1][2]

The dispute is commercially important because Xifaxan is one of Bausch Health’s largest products. The 550 mg tablet is approved for reducing the risk of overt hepatic encephalopathy recurrence in adults and for treatment of irritable bowel syndrome with diarrhea. Generic entry would affect a high-revenue product with limited therapeutic substitution in hepatic encephalopathy.

What drug and FDA application are at issue in Bausch v. Aurobindo?

The litigation concerns rifaximin tablets, particularly the 550 mg strength associated with Xifaxan.

Item	Information
Brand	Xifaxan
Active ingredient	Rifaximin
Dosage form	Oral tablets
Relevant strength	550 mg
Brand company	Salix Pharmaceuticals, Inc., a Bausch Health company
Plaintiff	Bausch Health Ireland Limited
Defendant	Aurobindo Pharma Limited
Court	U.S. District Court for the District of Delaware
Case number	2:23-cv-00170
Legal framework	Hatch-Waxman Act
Regulatory trigger	Aurobindo ANDA and related paragraph IV certification
Judicial district	District of Delaware

Aurobindo’s ANDA certification asserted that one or more patents listed for Xifaxan were invalid, unenforceable, or would not be infringed by the proposed generic. Bausch responded under 35 U.S.C. § 271(e)(2), the statutory provision that treats submission of an ANDA seeking approval before patent expiration as an act of infringement.

What patents protect Xifaxan and rifaximin tablets?

Xifaxan is protected by a layered patent estate covering rifaximin compositions, solid-state forms, pharmaceutical formulations, and therapeutic uses. The principal Orange Book-listed patents associated with rifaximin products have included the following families:

Patent	General subject matter	Commercial relevance
U.S. Patent No. 8,309,569	Rifaximin solid-state or polymorphic forms and related pharmaceutical compositions	Protects the active ingredient presentation used in the commercial product
U.S. Patent No. 8,642,573	Rifaximin compositions and dosage forms	Covers formulation and product characteristics
U.S. Patent No. 8,748,482	Rifaximin pharmaceutical compositions	Provides additional formulation protection
U.S. Patent No. 10,765,667	Rifaximin compositions and related manufacturing or formulation technology	Extends protection beyond the earlier rifaximin patents
U.S. Patent No. 11,020,361	Therapeutic use of rifaximin, including gastrointestinal indications	Creates method-of-use risk for approved Xifaxan indications

The precise patents asserted against Aurobindo must be determined from the complaint, exhibits, and the operative pleadings rather than from the complete Orange Book listing. Patent listings can change during litigation because patents may issue after an ANDA is filed, be delisted, or be added to an amended complaint.

The estate’s strength comes from its layered structure. An ANDA applicant may avoid one patent through a non-infringement position, a formulation change, or a section viii carve-out while remaining exposed to other patents covering the same product or an approved indication.

When does Xifaxan lose patent exclusivity?

The earliest rifaximin patent protection does not necessarily establish the first practical generic-entry date. The relevant date depends on which patents were asserted, whether any patent term adjustment or patent term extension applies, whether pediatric exclusivity is attached, and whether the parties settle.

The principal timing considerations are:

1. Earlier composition and solid-state patents may expire before later-issued formulation and method-of-use patents.
2. A generic applicant may obtain approval with a label that omits a patented indication.
3. A successful paragraph IV challenge can accelerate entry before the listed patent expiration dates.
4. A settlement can establish a licensed entry date that is earlier than the final asserted-patent expiration date.
5. FDA approval does not itself eliminate the risk of a separate patent-infringement action based on a launch.

For Xifaxan, the later-generation patents are commercially significant because they may extend protection beyond the first wave of rifaximin patents. Public Orange Book data should be read together with the litigation docket and any settlement agreement when estimating entry timing. [3]

What was Bausch’s infringement theory against Aurobindo?

Bausch’s case was based on the allegation that Aurobindo’s ANDA submission constituted artificial infringement of patents covering Xifaxan-related rifaximin products and uses.

The asserted theories in this type of action generally fall into four categories:

Formulation infringement

Bausch could argue that Aurobindo’s proposed tablets contain rifaximin in a protected composition, physical form, or pharmaceutical matrix. This type of claim focuses on the product described in the ANDA rather than on the commercial conduct of a future launch.

Solid-state or polymorph infringement

Rifaximin can exist in different solid-state forms. Claims directed to a particular form can create technical infringement issues involving crystallinity, water content, particle characteristics, stability, or conversion during manufacturing and storage.

Method-of-use infringement

The 550 mg product is associated with more than one approved indication. If Aurobindo’s proposed label includes an indication covered by a listed method-of-use patent, Bausch may assert induced infringement or direct infringement under the ANDA framework.

Manufacturing and process evidence

Bausch may seek discovery concerning Aurobindo’s manufacturing process, starting materials, drying conditions, granulation, tableting, and quality-control specifications. Process information can determine whether the resulting generic product falls within a composition or solid-state claim.

What is the Orange Book status of Xifaxan?

Xifaxan has been protected through multiple FDA-listed patents. The Orange Book identifies patents and regulatory exclusivity associated with approved products, but it does not resolve whether the patents are valid, infringed, or enforceable.

The Orange Book is relevant for three separate reasons:

• It identifies patents that an ANDA applicant must address.
• It establishes the regulatory basis for paragraph IV litigation.
• It provides the starting point for estimating potential generic approval dates.

An Orange Book listing does not guarantee that a patent will survive litigation. Conversely, a patent’s absence from the Orange Book does not eliminate all patent risk. Unlisted patents may still support infringement claims, subject to the limits of the Hatch-Waxman safe harbor and the facts of the proposed launch.

How does a paragraph IV challenge affect Aurobindo’s launch timing?

Aurobindo’s paragraph IV certification created the statutory basis for Bausch’s lawsuit. Once Bausch filed within the statutory period, FDA approval of the ANDA was generally subject to a 30-month stay, unless the court ordered otherwise or the litigation ended sooner. [4]

The practical launch sequence is:

Event	Effect
Aurobindo submits ANDA	FDA begins review and patent certifications are made
Paragraph IV notice is served	Brand company receives formal notice of the challenge
Bausch files suit	30-month stay is triggered under applicable Hatch-Waxman rules
Court resolves validity or infringement	Approval and launch risk become clearer
Settlement or dismissal	May establish a negotiated entry date
Final judgment for Aurobindo	Can permit approval before patent expiration, subject to FDA status
Final judgment for Bausch	Can block launch until the relevant patent barriers expire

Aurobindo’s commercial entry would also depend on FDA approval, manufacturing readiness, controlled distribution arrangements if applicable, and the scope of any final judgment or settlement.

What patent litigation affects Xifaxan generic entry?

The Aurobindo case is part of a broader pattern of generic challenges to rifaximin. Because Xifaxan has substantial sales and a relatively concentrated competitive market, multiple ANDA applicants have had incentives to challenge the same patent families.

The business effect of parallel litigation depends on whether the first challenger obtains:

• a judgment invalidating a core patent;
• a non-infringement ruling;
• a covenant or settlement permitting entry;
• 180-day exclusivity as a first applicant; or
• a license that permits later generic applicants to enter on the same or a subsequent date.

A judgment against one generic does not automatically determine every other defendant’s case. Claim construction, ANDA formulation differences, manufacturing evidence, and certification language can produce different outcomes.

How strong is the Bausch patent estate for Xifaxan?

The estate is stronger than a single-patent portfolio because it includes overlapping protection categories. Its principal strengths are:

• multiple patent families;
• coverage of both product characteristics and approved uses;
• later-issued patents that can extend the effective barrier;
• technical infringement questions that depend on confidential ANDA information;
• substantial commercial value supporting prolonged litigation and settlement negotiations.

The main vulnerabilities are standard for pharmaceutical portfolios:

• earlier priority dates may limit patent term;
• polymorph and formulation claims can face anticipation and obviousness challenges;
• method-of-use claims may be avoidable through label carving;
• overlapping claims can be narrowed during claim construction;
• a generic may challenge only the claims necessary to obtain approval.

The estate’s commercial durability therefore depends less on the number of listed patents than on whether at least one valid, enforceable claim blocks the proposed product or its approved label.

Did Bausch and Aurobindo settle the litigation?

The case docket and any later stipulation, dismissal order, or confidential settlement filing control the procedural status. A dismissal without a public merits judgment should not be treated as a finding that the asserted patents were valid or infringed.

Pharmaceutical patent settlements commonly include:

• a permitted generic-entry date;
• a license to certain patents;
• restrictions on authorized generic activity;
• release of infringement claims;
• confidentiality provisions;
• allocation of litigation costs;
• provisions addressing later-issued patents.

A settlement may resolve the specific Aurobindo case without resolving the broader Xifaxan patent landscape. Other ANDA defendants may remain in litigation or operate under different settlement terms.

What generic entry risks exist for Bausch Health?

The principal risk is accelerated erosion of Xifaxan revenue if Aurobindo or another ANDA applicant obtains approval and launches before the expected end of the brand’s commercial exclusivity period.

Revenue exposure

Xifaxan has been a major Bausch Health product, particularly because the 550 mg tablet is used chronically by many patients with hepatic encephalopathy. Revenue risk depends on:

• the number of approved generic entrants;
• whether entry is authorized for both major indications;
• generic pricing;
• payer substitution;
• authorized-generic arrangements;
• the timing of generic launch;
• the number of patients switching from branded Xifaxan.

A single generic entrant can produce substantial price pressure. Multiple entrants usually accelerate reimbursement-driven substitution and reduce brand retention.

Regulatory and labeling risk

Aurobindo could seek approval with a carve-out for an indication protected by a method-of-use patent. Such a strategy may allow approval for a remaining indication while preserving litigation over the carved-out use. The commercial impact would depend on pharmacy substitution rules and prescriber behavior.

Manufacturing and IP risk

Rifaximin’s solid-state characteristics and manufacturing controls create potential barriers to rapid generic replication. These barriers can increase development cost and complicate litigation, but they do not guarantee durable exclusivity. A generic applicant that has completed bioequivalence, stability, and manufacturing work may be positioned to launch promptly after a favorable judgment or settlement.

How does Xifaxan compare with other Bausch patent disputes?

Xifaxan differs from many conventional small-molecule cases because the commercial product is supported by several overlapping patent types rather than one basic compound patent alone.

Issue	Xifaxan	Typical single-product generic case
Core technology	Rifaximin composition, solid-state form, formulation, and uses	Often one composition or formulation family
Main litigation issue	Technical product characteristics and approved uses	Validity or direct infringement
Label strategy	Potential section viii carve-out	Often limited to one patented indication
Generic risk	Multiple patent layers and multiple challengers	Concentrated in fewer claims
Revenue effect	High because of chronic use and limited alternatives	Depends on therapeutic category
Settlement value	Potentially high because entry timing materially affects sales	Varies by product

Key Takeaways

• Bausch Health Ireland v. Aurobindo Pharma, No. 2:23-cv-00170, is a Hatch-Waxman case involving generic rifaximin and Bausch’s Xifaxan franchise.
• The dispute centers on patents covering rifaximin compositions, solid-state forms, formulations, and therapeutic uses.
• Aurobindo’s paragraph IV certification created the basis for Bausch’s infringement action and the statutory FDA approval stay.
• The Orange Book provides the patent framework but does not determine patent validity or infringement.
• Later-issued formulation and method-of-use patents may create barriers after earlier rifaximin patents expire.
• Generic launch timing depends on the operative patents, final docket disposition, FDA approval, and any settlement license.
• Xifaxan presents material revenue exposure because of chronic use, high brand sales, and the potential for rapid generic substitution.

FAQs About Bausch Health Ireland v. Aurobindo

What is case 2:23-cv-00170 about?

It is a District of Delaware Hatch-Waxman patent case involving Bausch Health Ireland’s challenge to Aurobindo’s proposed generic rifaximin product associated with Xifaxan.

Is Xifaxan a biologic subject to biosimilar competition?

No. Xifaxan contains rifaximin, a small-molecule antibiotic. Competition proceeds through the ANDA generic-drug pathway, not the biosimilar pathway under the Biologics Price Competition and Innovation Act.

Can Aurobindo launch rifaximin before every Xifaxan patent expires?

Potentially. A launch could occur after a successful invalidity or non-infringement ruling, under a settlement license, or with a label that avoids an asserted method-of-use claim. The answer depends on the specific final judgment and product label.

Do Orange Book patents prevent all generic rifaximin products?

No. They create listed patent barriers for the relevant approved product and require ANDA certifications. They do not prevent every possible rifaximin product or resolve patent validity.

Why are rifaximin polymorph patents important?

A polymorph patent can cover the physical form of the active ingredient used in a tablet. If the generic product uses the protected form, the patent may create infringement exposure even when the active ingredient itself is no longer protected by an earlier patent.

References

1. U.S. District Court for the District of Delaware. (2023). Bausch Health Ireland Limited v. Aurobindo Pharma Limited, No. 2:23-cv-00170. PACER docket.

2. Bausch Health Ireland Limited. (2023). Complaint for patent infringement, Bausch Health Ireland Limited v. Aurobindo Pharma Limited, No. 2:23-cv-00170. U.S. District Court for the District of Delaware.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.

4. 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).